Vikas Mehta
Has grant
Attending Pathologist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
DAIICHI SANKYO TAG RING STUDY
Open Date: 2026-04-01
Close Date:
Articles (5)
Year:
2026
Year:
2026
Patient selection for focal therapy (FT) of prostate cancer requires the assessment of MRI and biopsy results. However, there is currently little guidance for the utility of PSMA PET/CT in FT planning. We describe the case of a man originally considered an ideal candidate for FT based on biopsy and MRI who was found to have a contralateral lesion‐harboring cancer detected only on PSMA PET/CT. Trial Registration: ClinicalTrials.gov identifier: NCT05852041
Year:
2025
Interstitial lung disease (ILD) is present in over 60% of patients with systemic sclerosis (SSc) and is the leading cause of SSc-related deaths. Profibrotic monocyte-derived alveolar macrophages (MoAM) play a causal role in the pathogenesis of pulmonary fibrosis in animal models where their persistence in the niche requires signaling through Colony Stimulating Factor 1 Receptor (CSF1R). We hypothesized that the presence and proportion of MoAM in bronchoalveolar lavage (BAL) fluid from patients with SSc-ILD may be a biomarker of ILD severity. To test this hypothesis, we analyzed BAL fluid from 9 prospectively enrolled patients with SSc-ILD and 13 healthy controls using flow cytometry and single-cell RNA sequencing. Patients with SSc-ILD had more MoAM and interstitial macrophages in BAL fluid than healthy controls, and their abundance was associated with lung fibrosis severity. We identified changes in the MoAM transcriptome as a function of treatment with mycophenolate, an effective therapy for SSc-ILD. In SSc-ILD lung explants, spatial transcriptomics identified an expanded population of interstitial macrophages spilling into the alveolar space. Our findings suggest that the proportion of profibrotic MoAM and interstitial macrophages in BAL fluid may serve as a biomarker of SSc-ILD and credential them as possible targets for therapy.
Year:
2025
Year:
2023
Collaborators (17)
Akash Patnaik
Deputy Chief for Translational Research
University of Chicago
Natalie Reizine
Assistant Professor
University of Chicago
Anthony Esposito
Assistant Professor
Northwestern University Feinberg School of Medicine
Ankit Agrawal
Research Professor
Northwestern University
Matthew Dapas
Research Assistant Professor
Northwestern University
Robert Tighe
Associate Professor
Duke Medicine
Nikolay Markov
Research Scholar
Sloan Kettering Institute
Alexander Misharin
Associate Professor
Northwestern University Feinberg School of Medicine
Ashley Ross
Northwestern University Feinberg School of Medicine
GR Scott Budinger
Professor of Medicine
Northwestern University
Ximing Yang
Professor and Chief of Urological Pathology
Northwestern Medicine
Cara Gottardi
Professor
Northwestern University Feinberg School of Medicine
Chitaru Kurihara
-
Monique Hinchcliff
Associate Professor
Yale University
Hiam Abdala Valencia
Associate Professor
Northwestern University
Angela Christine Argento
MD/Assistant Professor of Medicine
Northwestern University Feinberg School of Medicine
Nikita Joshi
Northwestern University
Make your next move.
Prepare your application
Review drafts before you send them.